Study of Pembrolizumab Plus MK-1084 in NSCLC with KRAS G12C Mutations
The study aims to evaluate the safety and efficacy of MK-1084 in treating NSCLC patients with KRAS G12C mutations.
Phase III
Oncology / NSCLC
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing trial of MK-1084 in combination with Pembrolizumab for NSCLC patients with KRAS G12C mutations could significantly impact treatment options in oncology. Positive trial results may lead to enhanced market positioning and influence clinical guidelines for targeted therapies in this patient population.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and safety data for MK-1084, as well as any potential regulatory filings based on outcomes.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.